Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study.

Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study. Acta Haematol. 2019 May 15;:1-9 Authors: Zhu XF, He HL, Wang SQ, Tang JY, Han B, Zhang DH, Wu LQ, Wu DP, Li W, Xia LH, Zhu HL, Liu F, Shi HX, Zhang X, Zhou F, Hu JD, Fang JP, Chen XQ, Ye TZ, Liang YM, Jin J, Zhang FK Abstract Aplastic anemia (AA) is a hematologic disease characterized by pancytopenia and hypocellular bone marrow, potentially leading to chronic anemia, hemorrhage, and infection. The China Aplastic Anemia Committee and British Committee for Standards in Haematology guidelines recommend hematopoietic stem-cell transplantation (HSCT) or immunosuppressive therapy (IST) comprising antithymocyte globulin (ATG) with cyclosporine (CsA) as initial treatment for AA patients. With limited epidemiological data on the clinical management of AA in Asia, a prospective cohort registry study involving 22 AA treatment centers in China was conducted to describe the disease characteristics of newly diagnosed AA patients and investigate real-world treatment patterns and patient outcomes. Of 340 AA patients, 72.9, 12.6, and 3.5% were receiving IST, traditional Chinese medicine, and HSCT, respectively, at baseline; only 22.2% of IST-treated patients received guideline-recommended ATG with CsA initially. Almost all patients received supportive care (95.6%) as blood transfusion (97.8%), antibiotics (63.7%), and/or hematopoietic growth factors (58.2%). Overall, 64.8% achie...
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research

Related Links:

Abstract Aplastic anemia (AA) is also referred as idiopathic aplastic anemia (IAA) it is stop producing new blood cells, which is leads to abnormal hematological syndrome such as pancytopenia and suppression of hypo-cellular bone marrow. The pathophysiology of AA in most of case is immune mediated and its stimulated type 1 cytotoxic T cells implication. There were exact consistent test for diagnosis of IAA is not yet available still now; hence, the most of the cases were identified with in severe or very severe stages. Recently, the deviant immune response and hematopoietic cells deficiencies are being defined in ...
Source: Current Pharmaceutical Biotechnology - Category: Biotechnology Authors: Tags: Curr Pharm Biotechnol Source Type: research
Immune checkpoint inhibitors are able to reactivate the immune system therefore enhance the anti-tumor effects. However, over-activated T cells may induce immune related adverse events (irAEs). Hematological irAEs are rarely reported, which mainly represent as mono-lineage cytopenia or pancytopenia, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), neutropenia and aplastic anemia, sometimes even lethal, such as hemophagocytic lymphohistiocytosis. The clinical manifestations of hematological irAEs will be summarized and recommendations of diagnosis and treatment are proposed. 
 DOI: 10.3779/j.is...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsSevere hypercalcemia and aplastic anemia are potential paraneoplastic syndromes of adult T-type lymphoblastic lymphoma, with fatal short-term outcome.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Publication date: Available online 29 August 2019Source: The Lancet HaematologyAuthor(s): Jong Wook Lee, Sung-Eun Lee, Chul Won Jung, Silvia Park, Hiroyuki Keta, Soo Kyeong Park, Jin-A Kim, Il-Hoan Oh, Jun Ho JangSummaryBackgroundAplastic anaemia is a rare, life-threatening condition, characterised by pancytopenia with hypocellular bone marrow. Haematopoietic stem cells and most progenitor cells express thrombopoietin receptor (c-MPL). Romiplostim is a peptibody with c-MPL agonist activity that stimulates endogenous thrombopoietin production and leads to promoting the proliferation and differentiation of megakaryocytes in ...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Authors: Yin X, Yang J, Liu Y, Zhang J, Xin C, Zhao H, Wang W, Shi X, Cui Z, Li G, Zhao C, Liu X Abstract The current study aimed to explore the levels of leptin (LEP) and LEP receptor (LEP-R) on the progression of aplastic anemia (AA) with bone marrow fat conversion. An AA model was developed by infusing C57BL/6 lymph node cells into BALB/c mice. At 0, 3, 6, 9, 12, 15 and 18 days after modeling, routine blood counts, bone marrow biopsy slides, lymphocyte subsets (CD4+ and CD8+ T cells) and cytokine levels [including interleukin (IL)-2, IL-4, IL-5 and interferon-γ] were assessed. LEP and LEP-R levels in perip...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Aplastic anaemia (AA) is a rare and heterogeneous disorder. AA results in pancytopenia and a hypocellular bone marrow in the absence of an abnormal infiltrate, major dysplasia or marrow fibrosis. In children, most cases are idiopathic and caused by T lymphocyte-mediated destruction of haemopoietic stem and progenitor cells (HSPC's). Inherited bone marrow failure syndromes (IBMFS) account for around 20% of cases and have to be excluded. This can be challenging but has specific implications for management.
Source: Paediatrics and Child Health - Category: Pediatrics Authors: Tags: Symposium: haematology Source Type: research
Aplastic anemia (AA) is a hematologic disease characterized by pancytopenia and hypocellular bone marrow, potentially leading to chronic anemia, hemorrhage, and infection. The China Aplastic Anemia Committee and British Committee for Standards in Haematology guidelines recommend hematopoietic stem-cell transplantation (HSCT) or immunosuppressive therapy (IST) comprising antithymocyte globulin (ATG) with cyclosporine (CsA) as initial treatment for AA patients. With limited epidemiological data on the clinical management of AA in Asia, a prospective cohort registry study involving 22 AA treatment centers in China was conduct...
Source: Acta Haematologica - Category: Hematology Source Type: research
Roser Calvo* Patient Safety, Safety Science, AstraZeneca Pharmaceuticals, Gaithersburg, MD, United States Immune-related hematological adverse events are amongst the rare but potentially life-threatening complications of immune checkpoint inhibitors. The spectrum of these toxicities is broadening as the number of patients exposed to these agents is increasing. Yet, they are still relatively unknown to many clinicians, possibly due to a lack of specific diagnostic criteria, which poses a challenge for their recognition and proper reporting, and partly due to their low incidence, often too low to be noted in most c...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 24 April 2019Source: Life SciencesAuthor(s): Sarmistha Adhikari, Paramita MandalAbstractAimsAplastic anaemia is a rare disorder characterized by peripheral pancytopenia and hypocellular bone marrow. Recent advancement of miRNA technologies, new promising therapy using small molecule inhibitors was suggested as efficient treatment option. Therefore, the study was undertaken to identify the significantly altered miRNA (miR-1202-upregulation) among aplastic anaemia patients compared to healthy controls by global miRNA expression profiling of bone marrow.Materials and methodsmiRNA and gene ex...
Source: Life Sciences - Category: Biology Source Type: research
In conclusion, AUB secondary to AA can be acute and severe. Hemostasis is more difficult due to progressive pancytopenia. For young women with future fertility desire, LNG-IUS following hysteroscopic resection of endometrial functional layer is a safe and effective way against endometrial ablation or hysterectomy.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Anemia | Aplastic Anemia | Blood Transusion | China Health | Epidemiology | Hematology | Pancytopenia | Restasis | Stem Cell Therapy | Stem Cells | Study | Switzerland Health | Transplants | UK Health